Nuvation Bio Inc. Class A Common Stock vs Valero Energy Corporation — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.22 (market cap $1.74B), while Valero Energy Corporation trades at $442.5 (market cap $127.78B). The key difference: Valero Energy Corporation is far larger — about 73.4× Nuvation Bio Inc. Class A Common Stock's market cap, and Valero Energy Corporation pays a 1.08% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Valero Energy Corporation for 56 Days on average.
| NUVB | VLO | |
|---|---|---|
Market Cap | $1.74B | $127.78B |
Volume | 9,289,619 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $9.54 | $443.80 |
52-Week Low | $3.41 | $156.39 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $1.33B | $131.26B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Valero Energy (VLO) trades at $424.10, up 1.16% today, near its 52-week high. The stock exhibits bullish technical signals with strong moving average alignment and has beaten earnings estimates for three consecutive quarters. Revenue declined to $122.69 billion in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a $408.10 price target, and recent news highlights institutional buying and refining margin strength.
Outlook remains positive driven by earnings beats and supportive refining margins, but risks include potential diesel export policy changes and volatile energy markets. The stock's high RSI suggests near-term overbought conditions, yet fundamental improvements and strong cash flow projections for 2026 provide a solid foundation for continued investor interest.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →